Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

CAPS Rating: 4 out of 5

A biopharmaceutical company that acquires and advances a diversified portfolio of drug candidates, with a focus on oncology, urology and other critical health challenges for which there are few other treatment options.

Results 1 - 20 of 70 : 1 2 3 4 Next »

Recs

0
Member Avatar TMFDeej (99.23) Submitted: 5/12/2015 12:36:58 PM : Outperform Start Price: $6.70 SPPI Score: +5.83

Letter: Armistice Capital Active On Spectrum Pharmaceuticals

http://activiststocks.com/letters-by-activists/2015/5/12/letter-armistice-capital-active-on-spectrum-pharmaceuticals

Recs

0
Member Avatar loangolfer (< 20) Submitted: 5/1/2015 9:32:57 AM : Outperform Start Price: $5.73 SPPI Score: +22.31

ZZlanger likes it and he is all over these bio-med things.

Recs

0
Member Avatar CMFMLove (37.01) Submitted: 4/3/2015 11:48:53 AM : Outperform Start Price: $5.90 SPPI Score: +17.08

Spectrum’s stock price collapsed after a court ruling in February that invalidated the company's patent claims on cancer drug Fusilev. Many assume that the company ‘ain’t got nothin’ left’. However, Spectrum has two other drugs in development: poziotinib for breast cancer and SPI-2012 for chemotherapy-induced neutropenia. Both have the long-term blockbuster potential. Spectrum announced positive Phase 2 results for SPI-2012 in March at its analyst day. It will take while to see if these new drugs will pan out, but I think it is worth a small position at these prices.

Recs

0
Member Avatar TerryFool (81.09) Submitted: 2/13/2015 1:39:47 PM : Outperform Start Price: $5.98 SPPI Score: +17.98

BP 6 TP 13

Recs

5
Member Avatar zzlangerhans (99.79) Submitted: 1/8/2014 11:56:59 PM : Outperform Start Price: $8.54 SPPI Score: -28.60

It looks like I've only got six slots left for CAPS picks and I'm going to blow one of them on Spectrum, a company I've been critical of in the past but could be turning a corner. After several quarters of decline in Fusilev revenues, there was a sharp uptick last quarter which may indicate that Fusilev has acquired a foothold from which they won't be easily displaced by the reappearance of generic leucovorin. Zevalin and Folotyn are performing respectably, and pivotal data for captisol-enabled melphalan in Q2 could provide further lift. There will also likely be a PDUFA for Belinostat in late 2014. Marqibo and apaziquone are the wild cards in the mix, but there is certainly potential for positive catalysts with phase III trials in 2014.

A former high flyer, Spectrum was anemic in the biopharma bull market of 2013. Raj got his bonus in 2012 and seems to be resting on his laurels for now, but I believe eventually the potential here will lift the stock even in the absence of self-promotion.

Recs

0
Member Avatar BlizzardInv (< 20) Submitted: 12/13/2013 3:59:22 PM : Outperform Start Price: $9.12 SPPI Score: -37.10

Totally a speculative bet.

the company is definitely improving though and their pipeline is pretty promising. new drugs possibly coming out in the next few years and their way of aquisitioning other companies is pretty awesome.

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 9/26/2013 5:46:03 AM : Underperform Start Price: $8.14 SPPI Score: +34.05

top hs pattern

Recs

0
Member Avatar TerryHoodSr (77.37) Submitted: 5/27/2013 3:52:38 PM : Outperform Start Price: $7.90 SPPI Score: -36.87

5 YR REV growth 90%

Recs

0
Member Avatar MajorBob04 (99.57) Submitted: 4/8/2013 12:38:29 PM : Outperform Start Price: $7.01 SPPI Score: -31.47

Overreaction by the market. They have low PE, two other approved drugs and if there's a shortage of generic drug sales and the price will rebound.

Recs

1
Member Avatar GunnarVagotis (96.00) Submitted: 4/2/2013 3:32:51 PM : Outperform Start Price: $7.20 SPPI Score: -32.69

I have held NBIX for about 5 years and am just now in the black after having been deeply in the red the entire time. What's the message? GO LONG IN A BUNCH MORE SPECULATIVE BIOTECH STOCKS.

Recs

0
Member Avatar CarlosDK (21.22) Submitted: 2/16/2013 7:57:25 AM : Outperform Start Price: $11.52 SPPI Score: -69.67

big IHS tos

Recs

0
Member Avatar Avicii (< 20) Submitted: 10/16/2012 7:18:14 PM : Outperform Start Price: $11.73 SPPI Score: -77.92

This company is gold

Recs

0
Member Avatar mhonarvarthe2nd (< 20) Submitted: 8/23/2012 12:54:12 PM : Outperform Start Price: $11.63 SPPI Score: -81.80

will run back to 17-18 range again

Recs

0
Member Avatar okiedivot (43.54) Submitted: 7/24/2012 10:07:29 AM : Outperform Start Price: $15.43 SPPI Score: -102.32

Generic not catching on.

Recs

0
Member Avatar tyfoidhana (< 20) Submitted: 6/30/2012 2:54:58 AM : Outperform Start Price: $15.04 SPPI Score: -97.07

CEO has a clue

Recs

0
Member Avatar Zhraath (40.98) Submitted: 5/7/2012 1:39:40 PM : Outperform Start Price: $10.61 SPPI Score: -76.79

it's highly unlikely that a cancer patient will switch to the generic alternative. This has to be the most undervalued stock I've seen in a long time.

Recs

0
Member Avatar SorrySam (75.73) Submitted: 4/27/2012 6:05:48 AM : Outperform Start Price: $10.48 SPPI Score: -75.79

Kevin Tang

Recs

0
Member Avatar RBuskey106 (62.54) Submitted: 4/4/2012 12:55:32 PM : Outperform Start Price: $11.83 SPPI Score: -83.90

Chart Play

Recs

0
Member Avatar badomen (< 20) Submitted: 2/28/2012 3:05:20 PM : Outperform Start Price: $13.99 SPPI Score: -94.98

With two profitable drugs increasing sales each quarter and three more attractive drugs expected to reach approval this year, SPPI is one of the most attractive biotech stocks out there. Profits should rise each quarter as well as stock price, and the stock is a good acquisition candidate.

Recs

0
Member Avatar AugieAugster (< 20) Submitted: 1/24/2012 3:01:51 PM : Outperform Start Price: $15.05 SPPI Score: -104.74

Eoquin first and foremost is going to bring in $500M a year starting in 2013.

On top of that you have F and Z picking up significant steam and B, which looks to have positive results from it's trial.

Not to mention many other drugs in the pipeline.

Results 1 - 20 of 70 : 1 2 3 4 Next »

Featured Broker Partners


Advertisement